NCT02137863

Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy

Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: TC Erciyes University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study was to evaluate the effects of dexmedetomidine on renal function, hormonal and hemodynamic parameters in contrast media induced diabetic patients.

Detailed description

Contrast nephropathy may occur after using intravenous contrast media and may result in acute renal failure. Contrast nephropathy usually reversible but in some cases it can be permanent. This situation increase the time of hospitalization and mortality of the patients. Although the only proved prevention from contrast nephropathy method is hydration, infusion of dexmedetomidine may keep the renal functions.

Conditions

• Radiographic Contrast Agent Nephropathy

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Intravenously 1μg/kg/10min administered just before the procedure. 1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
DRUG	0.9 % NaCl	During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
DRUG	0.9 % NaCl	100 ml/10min infusion just before the angiography 1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure

Timeline

• Start date: 2011-06-01
• Primary completion: 2012-06-01
• Completion: 2012-07-01
• First posted: 2014-05-14
• Last updated: 2014-05-14